Surgically Treated Clear Cell Sarcomas - What Influences Outcomes?

Area of Science:

• Oncology
• Surgical Pathology
• Medical Research

Background:

• Clear cell sarcoma (CCS), also known as melanoma of soft parts, is a rare soft-tissue malignancy.
• CCS exhibits melanocytic differentiation and commonly metastasizes to lymph nodes and lungs.
• Patients with metastatic CCS have a poor oncologic prognosis, with limited effective adjuvant treatments.

Purpose of the Study:

• To evaluate the oncologic outcomes of clear cell sarcoma patients.
• To identify prognostic factors influencing survival in CCS.
• To assess recurrence patterns and survival rates in a cohort of CCS patients.

Main Methods:

• Retrospective analysis of 29 CCS patients from a prospectively maintained surgical database (2004-2020).
• Evaluation of overall survival (OS) and recurrence-free survival (RFS) rates.
• Analysis of metastasis at presentation, recurrence patterns, and surgical margins.

Main Results:

• The 5-year OS, local recurrence-free survival (LRFS), and distant recurrence-free survival (DRFS) were 53%, 56%, and 35%, respectively.
• Nodal metastasis occurred in 24% of patients, with 19% having positive surgical margins.
• Metastasis at presentation was associated with significantly poorer survival (p=0.016).

Conclusions:

• Clear cell sarcoma is an aggressive malignancy with a high propensity for metastasis and poor overall survival.
• Metastasis at presentation is a critical negative prognostic factor.
• Complete surgical resection of recurrences is advised, and further research into novel chemotherapeutic and targeted therapies is warranted to improve CCS prognosis.